Vanda Pharmaceuticals (VNDA) Change in Receivables (2010 - 2026)

Vanda Pharmaceuticals has disclosed Change in Receivables across 17 years of filings, most recently posting $2.3 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $2.3 million, up 192.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (up 56.25% YoY), and the FY2025 annual result was $7.5 million, down 42.65% from the prior year.
• Change in Receivables came in at $2.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $4.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $9.1 million in Q2 2023 to a low of -$8.9 million in Q1 2023.
• The 5-year median for Change in Receivables is $2.3 million (2026), against an average of $1.4 million.
• Peak annual rise in Change in Receivables reached 662.42% in 2023, while the deepest fall reached 829.85% in 2023.
• Vanda Pharmaceuticals' Change in Receivables stood at $4.1 million in 2022, then grew by 18.79% to $4.8 million in 2023, then dropped by 8.37% to $4.4 million in 2024, then dropped by 8.03% to $4.1 million in 2025, then plunged by 42.75% to $2.3 million in 2026.
• The last three Change in Receivables figures came in at $2.3 million (Q1 2026), $4.1 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.